Paul Naaber
- Infectious Diseases top 2%
- Molecular Biology top 10%
- Food Science top 2%
- Physiology top 5%
- Epidemiology top 10%
- Co-authors
- BjörksténMarika MikelsaarEpp SeppBengt BjörksténSiiri KõljalgMaire VasarKaja JulgeRaik-Hiio Mikelsaar
- Topics
- Antibiotic Resistance in Bacteria (12 papers)Clostridium difficile and Clostridium perfringens research (11 papers)SARS-CoV-2 and COVID-19 Research (9 papers)
In The Last Decade
Paul Naaber
53 papers receiving 2.3k citations
Hit Papers
Peers
Comparison fields: 5 of 109
- Infectious Diseases 863
- Molecular Biology 696
- Food Science 521
- Physiology 460
- Epidemiology 315
Countries citing papers authored by Paul Naaber
This map shows the geographic impact of Paul Naaber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Naaber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Naaber more than expected).
Fields of papers citing papers by Paul Naaber
This network shows the impact of papers produced by Paul Naaber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Naaber. The network helps show where Paul Naaber may publish in the future.
Co-authorship network of co-authors of Paul Naaber
This figure shows the co-authorship network connecting the top 25 collaborators of Paul Naaber. A scholar is included among the top collaborators of Paul Naaber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Naaber. Paul Naaber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 2 | |
| 3 | Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective studybreakdown → | 379 |
| 4 | 7 | |
| 5 | 26 | |
| 6 | 28 | |
| 7 | 35 | |
| 8 | 18 | |
| 9 | 12 | |
| 10 | 19 | |
| 11 | 81 | |
| 12 | 7 | |
| 13 | 2 | |
| 14 | 13 | |
| 15 | 20 | |
| 16 | 29 | |
| 17 | 14 | |
| 18 | 84 | |
| 19 | 19 | |
| 20 | 34 |
About Paul Naaber
Paul Naaber is a scholar working on Applied Microbiology and Biotechnology, Molecular Medicine and Infectious Diseases, having authored 56 papers that have together received 2.5k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (12 papers), Clostridium difficile and Clostridium perfringens research (11 papers) and SARS-CoV-2 and COVID-19 Research (9 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (102 citations), Infectious Diseases (863 citations) and Immunology and Allergy (278 citations). Paul Naaber has collaborated with scholars based in Estonia, Norway and Sweden. Frequent co-authors include Björkstén, Marika Mikelsaar, Epp Sepp, Bengt Björkstén, Siiri Kõljalg, Maire Vasar, Kaja Julge, Raik-Hiio Mikelsaar, Pärt Peterson and Kai Kisand. Their work appears in journals such as PLoS ONE, Clinical Infectious Diseases and Journal of Clinical Microbiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.